BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8614266)

  • 1. Pharmacology of L-744,453, a novel nonpeptidyl endothelin antagonist.
    Williams DL; Murphy KL; Nolan NA; O'Brien JA; Lis EV; Pettibone DJ; Clineschmidt BV; Krause SM; Veber DF; Naylor EM; Chakravarty PK; Walsh TF; Dhanoa DM; Chen A; Bagley SW; Fitch KJ; Greenlee WJ
    Life Sci; 1996; 58(14):1149-57. PubMed ID: 8614266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of L-754,142, a highly potent, orally active, nonpeptidyl endothelin antagonist.
    Williams DL; Murphy KL; Nolan NA; O'Brien JA; Pettibone DJ; Kivlighn SD; Krause SM; Lis EV; Zingaro GJ; Gabel RA
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1518-26. PubMed ID: 8531124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.
    Nishikibe M; Ohta H; Okada M; Ishikawa K; Hayama T; Fukuroda T; Noguchi K; Saito M; Kanoh T; Ozaki S; Kamei T; Hara K; William D; Kivlighn S; Krause S; Gabel R; Zingaro G; Nolan N; O'Brien J; Clayton F; Lynch J; Pettibone D; Siegl P
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1262-70. PubMed ID: 10336515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of A-216546: a highly selective antagonist for endothelin ET(A) receptor.
    Wu-Wong JR; Dixon DB; Chiou WJ; Dayton BD; Novosad EI; Adler AL; Wessale JL; Calzadilla SV; Hernandez L; Marsh KC; Liu G; Szczepankiewicz B; von Geldern TW; Opgenorth TJ
    Eur J Pharmacol; 1999 Feb; 366(2-3):189-201. PubMed ID: 10082200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonist activity of [Thr18,gamma-methylleucine19]endothelin-1 in human endothelin receptors.
    Masuda Y; Sugo T; Kikuchi T; Satoh M; Fujisawa Y; Itoh Y; Wakimasu M; Ohtaki T
    Eur J Pharmacol; 1997 May; 325(2-3):263-70. PubMed ID: 9163574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a novel bifunctional endothelin receptor antagonist, IRL 3630A, on guinea pig respiratory mechanics.
    Makatani M; Fujitani Y; Takimoto M; Oda K; Sasaki Y; Hori S; Inui T; Sakaki J; Okada T; Hoshiko K; Yamamura T
    Eur J Pharmacol; 2000 Oct; 406(1):139-47. PubMed ID: 11011045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic characterization of S-1255, a highly potent and orally active endothelin A receptor antagonist.
    Iwasaki T; Mihara S; Shimamura T; Kawakami M; Masui M; Hayasaki-Kajiwara Y; Naya N; Ninomiya M; Fujimoto M; Nakajima M
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):471-82. PubMed ID: 11300660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization of PABSA, an orally active and highly potent endothelin-receptor antagonist.
    Iwasaki T; Mihara S; Shimamura T; Kawakami M; Hayasaki-Kajiwara Y; Naya N; Fujimoto M; Nakajima M
    J Cardiovasc Pharmacol; 1999 Jul; 34(1):139-47. PubMed ID: 10413080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelin-1 (ET-1)-induced contraction in rat isolated trachea: involvement of ETA and ETB receptors and multiple signal transduction systems.
    Henry PJ
    Br J Pharmacol; 1993 Sep; 110(1):435-41. PubMed ID: 8220905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a potent and selective endothelin-B receptor antagonist, IRL 2500.
    Balwierczak JL; Bruseo CW; DelGrande D; Jeng AY; Savage P; Shetty SS
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S393-6. PubMed ID: 8587424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist.
    Wilson C; Hunt SJ; Tang E; Wright N; Kelly E; Palmer S; Heys C; Mellor S; James R; Bialecki R
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1085-91. PubMed ID: 10454481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BMS-182874 is a selective, nonpeptide endothelin ETA receptor antagonist.
    Webb ML; Bird JE; Liu EC; Rose PM; Serafino R; Stein PD; Moreland S
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1124-34. PubMed ID: 7891325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist.
    Hoshino T; Yamauchi R; Kikkawa K; Yabana H; Murata S
    J Pharmacol Exp Ther; 1998 Aug; 286(2):643-9. PubMed ID: 9694915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist.
    Wu C; Chan MF; Stavros F; Raju B; Okun I; Mong S; Keller KM; Brock T; Kogan TP; Dixon RA
    J Med Chem; 1997 May; 40(11):1690-7. PubMed ID: 9171878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethenesulfonamide derivatives, a novel class of orally active endothelin-A receptor antagonists.
    Harada H; Kazami J; Watanuki S; Tsuzuki R; Sudoh K; Fujimori A; Tanaka A; Tsukamoto S; Yanagisawa I
    Chem Pharm Bull (Tokyo); 2001 May; 49(5):606-12. PubMed ID: 11383615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelins and endothelin receptor antagonists: binding to plasma proteins.
    Wu-Wong JR; Chiou WJ; Hoffman DJ; Winn M; von Geldern TW; Opgenorth TJ
    Life Sci; 1996; 58(21):1839-47. PubMed ID: 8637410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of [125I]-PD164333, an ETA selective non-peptide radiolabelled antagonist, in normal and diseased human tissues.
    Davenport AP; Kuc RE; Ashby MJ; Patt WC; Doherty AM
    Br J Pharmacol; 1998 Jan; 123(2):223-30. PubMed ID: 9489609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use.
    Clozel M; Ramuz H; Clozel JP; Breu V; Hess P; Löffler BM; Coassolo P; Roux S
    J Pharmacol Exp Ther; 1999 Aug; 290(2):840-6. PubMed ID: 10411600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist.
    Opgenorth TJ; Adler AL; Calzadilla SV; Chiou WJ; Dayton BD; Dixon DB; Gehrke LJ; Hernandez L; Magnuson SR; Marsh KC; Novosad EI; Von Geldern TW; Wessale JL; Winn M; Wu-Wong JR
    J Pharmacol Exp Ther; 1996 Feb; 276(2):473-81. PubMed ID: 8632312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methods for assessing endothelin ETA-receptor antagonists in preclinical studies.
    Okada M; Siegl PK; Nishikibe M
    Methods Find Exp Clin Pharmacol; 2002; 24(6):361-70. PubMed ID: 12224443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.